J. Albert et al. / Journal of Organometallic Chemistry 815-816 (2016) 44e52
51
4JHH ¼ 1.7 Hz, 1H, p-py), 7.29e7.26 (m, partially overlapped with
4JHH ¼ 0.9 Hz, 1H, 4), 7.01 (td, JHH ¼ 7.6 Hz, JHH ¼ 1.5 Hz, 1H, 3),
3
3
3
13
1
CHCl
3
, 3H, 5 þ m-py), 7.12e7.07 (m, overlapped with 4 of trans-N,N,
6.29 (d, JHH ¼ 7.5 Hz, 1H, 2), 3.93 (s, 3H, 13), 1.56 (s, 3H, 15). C{ H}
3
4
1
J
3
H, 4), 6.94 (td,
J
HH ¼ 7.6 Hz,
J
HH ¼ 1.5 Hz, 1H, 3), 6.86 (d,
NMR (101 MHz, CDCl
3
þ py-d
5
, 298 K), d (ppm) (compound 5): 177.6
3
3
3
HH ¼ 8.6 Hz, 2H, 9), 6.58 (dd, JHH ¼ 7.8 Hz, JHH ¼ 0.7 Hz, 1H, 2),
(s, 14), 175.9 (s, 7), 166.4 (s, 12), 157.3 (s, 1), 151.9 (s, 8), 146.7 (s, 6),
133.0 (s, 2),131.5 (s, 3),130.2 (s,10),129.2 (s,11),129.1 (s, 5),124.5 (s,
4), 123.1 (s, 9), 52.2 (s, 13), 24.5 (s, 15). Due to the rapid exchange
13
1
.95 (s, 3H, 13), 1.86 (s, 3H, 15). C{ H} NMR (101 MHz, CDCl
3
,
2
98 K), (ppm): [trans-N,N] 177.6 (14), 175.9 (7), 166.4 (12), 157.4
d
(
1
5
(
1), 153.4 (o-py), 151.9 (8), 146.7 (6), 138.1 (p-py), 133.0 (2), 131.5 (3),
30.2 (10), 129.2 (11), 129.1 (5), 125.4 (m-py), 124.6 (4), 123.1 (9),
2.2 (13), 24.5 (15); [cis-N,N] 180.6 (14), 173.5 (7), 166.4 (12), 155.7
1),150.9 (8),149.9 (br s, o-py),145.3 (6),136.0 (br s, p-py),132.5 (2),
between coordinated and free pyridine-d
5
, carbon NMR signals of
coordinated pyridine-d were not observed.
5
1
31.1 (3), 129.6 (10), 128.9 (11), 128.1 (5), 124.2 (4), 123.8 (br s, m-
2.1.7. Preparation of solution B
Solution B was prepared by adding ca. 30 mg (30
to a suspension of compound 2 (ca. 6 mg) in 1 cm of CDCl
3
ꢀ1
py), 123.2 (9), 52.3 (13), 24.2 (15). IR (KBr, selected data),
y
(cm ):
mL) of pyridine-
3
1720 (C]O st, ester), 1604 (C]N st), 1586 (C]O st, terminal ace-
d
5
1
tato), 1378 (CeO st, terminal acetato), 1271 (CeCeO as st), 1108
(molar ratio pyridine-d
(400 MHz, CDCl
þ py-d
5
/compound
2
z
50e55).
H NMR
(
4
4
CeCeO sym st). MS-MALDI TOF (þ) (DHB), m/z: 422.9 (calcd.
3
5
, 298 K),
d
(ppm) (compound 6): 8.12 (s,
þ
23.0) [M ꢀ OAc] . Anal. Calcd. for C22
H
20
N
2
O
4
Pd: C 54.73%, H
1H, 7), 7.98 (br d, 2H, 10), 7.43 (m, 1H, 5), 7.31 (br signal, 2H), 7.11 (br
13
1
.18%, N 5.80%. Found: C 54.7%, H 4.3%, N 6.1%.
d, 2H, 9) 3.89 (s, 3H, 13). C{ H} NMR (101 MHz, CDCl
98 K), (ppm) (compound 6): 176.8 (s, 7), 166.2 (s, 12), 146.4 (s, 6),
131.8 (s, 3), 130.1 (br s, 2), 129.1 (s, 5), 124.9 (s, 4), 52.2 (s, 13). Due to
the rapid exchange between coordinated and free pyridine-d
carbon NMR signals of coordinated pyridine-d and some carbon
3
þ py-d
5
,
2
d
2.1.5. Preparation of compound 4
3
0
.100 g (0.132 mmol) of compound 2 were treated with 6 cm of
5
,
a solution pyridine in CH
2
Cl
2
0.064 M (0.384 mmol of pyridine). The
5
solution was allowed to stir at room temperature for 2 h, and
thereafter volatiles were evaporated under reduced pressure. Upon
addition of diethyl ether (4 cm ) a light yellow precipitate formed,
peaks of the cyclopalladated ligand could not be observed (C1 and
C8 e C11).
3
which was collected by filtration and air-dried (107 mg, 97% yield).
Compound 4 consists of a mixture of trans-N,N and cis-N,N isomers
in a 1.0 : 0.5 ratio. A similar result was obtained reacting 100 mg
2.1.8. Preparation of solution C
Solution C was prepared by adding ca. 30 mg (30
mL) of pyridine-
(
0.132 mmol) of compound 2 with 417 mg (ca. 5.3 mmol) of pyri-
d to a suspension of acetato-bridge cyclopalladated compound 1
5
3
3
dine in 10 cm of CH
2
Cl
this case, the H NMR in CDCl
showed that it consisted of a mixture of trans- and cis-N,N isomers
2
stirring at room temperature for 24 h. In
(6 mg, approx.) in deuterated water (ca. 1 cm ) (molar ratio pyri-
1
1
3
solution of the isolated compound 2
5 2
dine-d /compound 1 z 50e55). H NMR in D O revealed the
presence of the cationic complex 7, together with ortho-palladated
benzaldehyde and methyl 4-aminobenzoate in a 1.0 : 0.2 : 0.2 ratio.
1
in 1.0 : 0.6 ratio. H NMR (400 MHz, CDCl
3
, 298 K),
d
(ppm): [trans-
3
1
N,N] 8.93 (d,
J
HH ¼ 5.0 Hz, 2H, o-py), 8.12 (s, 1H, 7), 8.09 (d,
H NMR (400 MHz, D
2
O þ py-d
5
, 298 K), d (ppm); compound 7: 8.22
3
3
3
3
J
HH ¼ 9.2 Hz, 2H, 10), 7.88 (t,
J
HH ¼ 7.5 Hz, 1H, p-py), 7.51 (d,
(s, 1H, 7), 7.69 (d,
J
HH ¼ 8.8 Hz, 2H, 10), 7.58 (dd,
J
HH ¼ 7.5 Hz,
3JHH ¼ 8.4 Hz, 2H, 9), 7.60e7.41 (m, overlapped with 5 of cis-N,N,
4
J
HH ¼ 1.2 Hz, 1H, 5), 7.24 (td, JHH ¼ 7.5 Hz, JHH ¼ 1.0 Hz, 1H, 4), 7.11
3
4
3
4
3
3
H, m-py þ 5), 7.15e7.11 (m, overlapped with m-py, 9 and 4 of cis-
(td, JHH ¼ 7.6 Hz, JHH ¼ 1.5 Hz, 1H, 3), 7.02 (d, JHH ¼ 8.8 Hz, 2H, 9),
3
3
3 4
N,N, 1H, 4), 7.05 (t, JHH ¼ 7.6 Hz, 1H, 3), 6.20 (d, JHH ¼ 7.6 Hz, 1H, 2),
6.19 (dd, JHH ¼ 7.6 Hz, JHH ¼ 0.8 Hz, 1H, 2), 3.83 (s, 3H, 13), 1.90 (s,
3H, 15); ortho-palladated benzaldehyde: 10.50 (s, 1H, CH]O), 8.02
3
.92 (s, 3H, 13); [cis-N,N] 8.36 (br d, 2H, o-py), 8.16 (s, 1H, 7), 7.76 (br
3
3
3
4
d, 10), 7.60 (br t, JHH ¼ 7.4 Hz, 1H, p-py), 7.52e7.41 (m, overlapped
(d, JHH ¼ 7.5 Hz, 1H), 7.53 (dd, JHH ¼ 7.6 Hz, JHH ¼ 1.3 Hz, 1H), 7.30
3
3
4
4
with m-py, 10 and 5 of trans-N,N, 1H, 5), 7.24 (t, JHH ¼ 7.6 Hz, 1H, 3),
(td,
JHH ¼ 7.7 Hz,
J
HH ¼ 1.6 Hz, 1H), 7.13e7.06 ( JHH ¼ 1.1 Hz,
7
.15e7.11 (m, overlapped with 4 of trans-N,N, 3H, m-py þ 4 and 2),
partially obscured by 3 of 7, 1H), 1.90 (s, 3H, 15); methyl 4-
.00 (d, 3
101 MHz, CDCl
58.7 (1), 153.2 (o-py), 152.5 (8), 146.4 (overlapped with 6 of cis-
N,N, 6), 138.2 (p-py), 132.2 (2), 131.8 (3), 130.0 (10), 129.3 (11), 129.1
overlapped with 5 of cis-N,N, 5), 125.6 (m-py), 124.9 (overlapped
with m-py of cis-N,N, 4), 123.8 (9), 52.1 (13); [cis-N,N] 176.8 (7),
65.9 (12), 157.0 (1), 152.2 (8), 150.6 (o-py), 146.4 (overlapped with
of trans-N,N, 6), 137.5 (br s, p-py), 136.7 (2), 131.7 (3), 130.4 (10),
29.1 (overlapped with 5 of trans-N,N, 5), 128.9 (11), 124.9 (over-
lapped with 4 of trans-N,N, m-py), 124.6 (4), 122.5 (9), 52.3 (13). IR
J
HH ¼ 8.0 Hz, 2H, 9), 3.89 (s, 3H, 13). C{ H} NMR
13
1
aminobenzoate: 7.73 (d, JHH ¼ 8.9 Hz, 2H), 6.74 (d, JHH ¼ 8.9 Hz,
3
3
7
(
1
3
, 298 K), (ppm): [trans-N,N] 176.9 (7), 166.4 (12),
d
2H), 3.79 (s, 3H). Signal of exchangeable amino protons was not
2
observed in D O.
(
2.1.9. Preparation of solution D
1
6
1
Solution D was prepared by adding ca. 30 mg (30 mL) of pyri-
dine-d
5
to a suspension of chlorido-bridge cyclopalladated com-
3
pound 2 (ca. 6 mg) in deuterated water (ca. 1 cm ) (molar ratio
pyridine-d /compound 2 z 50e55). H NMR in D O revealed the
5 2
1
ꢀ
1
(
KBr, selected data),
y
(cm ): 1715 (C]O st), 1604 (C]N st), 1587
presence of the cationic complex 8, together with ortho-palladated
(
C]N st pyridine), 1277 (CeCeO as st), 1113 (CeCeO sym st). MS-
benzaldehyde and methyl 4-aminobenzoate in a 1.0 : 0.2 : 0.2 ratio.
þ
1
ESI (þ) {H
2
O:CH
3
OH (1:1)}, m/z: 881.0 (calcd. 881.0) [2 MꢀCl] ,
H NMR (400 MHz, D
2
O þ py-d
5
, 298 K),
d (ppm); compound 8: 8.16
þ
þ
3
8
02.0 (calcd. 802.0) [2 MꢀCl e py] , 423.0 (calcd. 423.0) [MꢀCl] .
Anal. Calcd. for C20 17ClN Pd: C 52.31%, H 3.73%, N 6.10%. Found:
C 51.9%, H 3.8%, N 6.3%.
(s, 1H, 7), 7.64 (d,
J
HH ¼ 8.4 Hz, slightly overlapped with 2H of
3
H
2 2
O
methyl 4-aminobenzoate, 2H, 10), 7.56 (d, JHH ¼ 7.5 Hz, 1H, 5), 7.22
3
(t,
J
HH ¼ 7.5 Hz, 1H, 4), 7.09e7.04 (m, overlapped with 1H of
3
metallated aldehyde, 1H, 3), 6.96 (d, JHH ¼ 8.4 Hz, 2H, 9), 6.12 (d,
3
2
.1.6. Preparation of solution A
J
HH ¼ 7.8 Hz, 1H, 2), 3.80 (s, 3H, 13); ortho-palladated benzalde-
3
Solution A was prepared by adding ca. 30 mg (30
to a suspension of compound 1 (ca. 6 mg) in 1 cm of CDCl
m
L) of pyridine-
hyde: 10.45 (s, 1H, CH]O), 7.98 (d,
J
HH ¼ 7.2 Hz, 1H), 7.47 (d,
HH ¼ 7.6 Hz, 1H), 7.09e7.04 (m, over-
lapped with 3 of 8, 1H); methyl 4-aminobenzoate: 7.68 (d,
3
3
3
d
5
3
J
HH ¼ 7.6 Hz, 1H), 7.27 (t,
J
1
(
(
1
molar ratio pyridine-d
400 MHz, CDCl
þ py-d
5
/compound
1
z
50e55).
H
NMR
3
3
5
, 298 K),
d
(ppm) (compound 5): 8.12 (s,
J
HH ¼ 8.5 Hz, slightly overlapped with 10 of 8, 2H), 6.72 (d,
3
3
3
H, 7), 8.08 (d, JHH ¼ 8.6 Hz, 2H, 10), 7.50 (d, JHH ¼ 8.6 Hz, 2H, 9),
JHH ¼ 8.5 Hz, 2H, 9), 3.76 (s, 3H, 13). Signal of exchangeable amino
3 4 3
7
.42 (dd, JHH ¼ 7.4 Hz, JHH ¼ 1.3 Hz, 1H, 5), 7.09 (td, JHH ¼ 7.4 Hz,
2
protons was not observed in D O.